Journal
ACTA ONCOLOGICA
Volume 53, Issue 10, Pages 1284-1297Publisher
INFORMA HEALTHCARE
DOI: 10.3109/0284186X.2014.941999
Keywords
-
Categories
Funding
- Novartis Oncology
- Ipsen AB
Ask authors/readers for more resources
Background. The diagnostic work-up and treatment of patients with neuroendocrine neoplasms (NENs) has undergone major recent advances and new methods are currently introduced into the clinic. An update of the WHO classification has resulted in a new nomenclature dividing NENs into neuroendocrine tumours (NETs) including G1 (Ki67 index <= 2%) and G2 (Ki67 index 3-20%) tumours and neuroendocrine carcinomas (NECs) with Ki67 index > 20%, G3. Aim. These Nordic guidelines summarise the Nordic Neuroendocrine Tumour Group's current view on how to diagnose and treat NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available